nContact receives FDA clearance for EPi-Sense cardiac ablation device

Published on January 18, 2013 at 1:19 AM · No Comments

nContact, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's modifications to its VisiTrax® cardiac ablation device, EPi-Sense®, now with embedded sensing capability. This next generation of technology includes sensors along the ablation device which provide real-time feedback to physicians conducting cardiac ablation procedures.

The EPi-Sense® device and its sensing technology allows electrophysiologists (EPs) to follow epicardial device positioning and lesion creation in real time by utilizing navigational mapping. From a safety perspective, the sensors use electrical feedback to ensure the device is properly positioned on cardiac tissue and energy is directed into the heart. Additionally, by using the sensors during epicardial ablation, the ablated tissue's electrical impulses can be measured to predict lesion completeness before repositioning the device.

"The EPi-Sense® is another step forward in advancing epicardial ablation techniques to address limitations of other ablation devices, potentially creating a better experience for physicians, and ultimately, patients," commented John Funkhouser, President of nContact, Inc.

nContact, a leading manufacturer of cardiac tools to treat arrhythmias, has pioneered the use of a multi-disciplinary, closed chest approach to ensure lesion completeness that interrupts electrical signals that cause arrhythmias. The Company's reputation for advancing technology in the epicardial ablation space is further enhanced by this technology innovation.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post